FAIL (the browser should render some flash content, not this).
phage therapies
Phage therapy may be described as bacteriophage biocontrol. Lytic phages by their very special nature seem to be good candidates for antibacterial therapy. The phage therapy has advantages over antibiotics therapy, that come from the unique phage nature. Phages present an exponential growth in the infection region, so that the “cure” is born at the infection site and they have the ability to overcome bacterial resistance. In fact, the emergence of antibiotic-resistant infections has opened a window of opportunity for phage therapy.

Full credit: BIOZENTRUM, UNIVERSITY OF BASEL / SCIENCE, PHOTO LIBRARY
Transmission electron micrograph (TEM) showing the start of lysis (destruction) of a rod-shaped bacterium by T4 bacteriophages (viruses that infect bacteria). Bacteriophages (ovals with stalks) infect the bacterium, commanding the cell's genetic machinery to code for its own replication. The bacteriophage population grows at the expense of the normal functioning of the cell. Weakened through neglect & overcrowded with bacteriophages, the plasma membrane binding the cell into a unit bursts. The bacterium is destroyed; the bacteriophages are released to infect other cells. Mag: X 40,000 (10x8).

Full credit: BIOZENTRUM, UNIVERSITY OF BASEL / SCIENCE, PHOTO LIBRARY
Transmission electron micrograph (TEM) showing lysis (destruction) of a rod-shaped bacterium by T4 bacteriophages (viruses that infect bacteria). Bacteriophages (light ovals with stalks) infect the bacterium, commanding the genetic machinery of the cell to code for its own replication. The bacteriophage population increases at the expense of the normal functioning of the cell. Weakened through neglect & overcrowed with bacteriophage progeny, the delicate plasma membrane binding the cells into a unit, bursts. The bacterium is destroyed; the bacteriophages are released to infect other cells. Mag: X 40,000 (10x8). (Photographer R.Bijlenga)
Resistance to antibiotics is one of the major challenges in medicine today. Mortality from infectious disease is one of the principal causes of death and the cost to society due to infectious disease morbidity is significant.

Two factors emphasize the urgent need to continue research and development into new and innovative drugs for infectious diseases:
    Today’s escalating antibiotic crisis is the direct result of large scale and indiscriminate over-use of anti-infective drugs.
    Pharmaceutical companies have exhausted the arsenal of known antibiotic classes. Currently, the launch of new antibacterial products usually includes stronger dose formulations of old antibiotic classes. This results in the development of more antibiotic resistant strains and increased resistance of current strains. New classes of antibiotics are desperately needed.
This enormous unmet need for effective antibacterial drugs has arisen from the rapid proliferation of bacterial pathogens that are resistant to the current repertoire of antibiotics directed against a limited set of targets. Pharmaceutical companies have been unable to respond to either the threat of resistant bacteria or to the opportunity to make breakthrough treatments.
Drugs currently in the pharmaceutical discovery and development pipeline are largely variants of existing drugs and will be rapidly rendered obsolete through the adaptation of previously acquired pathogen resistance mechanisms.
Additionally, the timeline for discovering new compounds in the pharmaceutical industry has lengthened, thereby further delaying the introduction of potential new treatments for bacterial disease.

Main microorganisms associated to Hospital Acquired Infections [HAI]:


Bacteria and its specific bacteriophage:


In the health market, phages can be used as a:
    Therapeutic agent to treat bacterial infections, especially those caused by multi-drug resistant microorganisms and against which there is no currently available or effective treatment modality, one application would target infection caused by vancomycin-resistant enterococci;
    Prophylactic in oral hygiene aimed at eliminating pathogenic bacteria.  Direct applications might include mouthwash and toothpaste;
    Topical biodegradable polymer matrix to assist in wound healing;
    Research agent in clinical microbiology and epidemiology.
    Monitoring system for the bacterial contamination in the hospitals environment.

InnoPhage, Ltd - Innovative Bacteriophage Solutions